Journal of neurology · 2025
Predictors of achieving minimal manifestations or better status in ocular myasthenia gravis with immunotherapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Komatsu Teppei, Motegi Haruhiko, Mimori Masahiro, Okumura Motohiro, Masui Marina, Kida Hiroyuki, Ozawa Masakazu, Matsuno Hiromasa, Sakuta Kenichi, Bono Keiko, Sakai Kenichiro, Mitsumura Hidetaka, Iguchi Yasuyuki
Аннотация
BACKGROUND: Ocular myasthenia gravis (MG), while less severe than generalized MG, significantly impairs quality of life due to its impact on vision and daily activities. Immunotherapy is a key treatment, yet the optimal timing for initiation remains undefined.
OBJECTIVE: To identify predictive factors for achieving minimal manifestations (MM) or better status in ocular MG patients receiving immunotherapy, with a focus on the role of early intervention.
METHODS: We conducted a retrospective analysis of 48 ocular MG patients treated at our institution. Patients were categorized based on whether they achieved MM or better status. Clinical variables were analyzed using univariate, receiver-operating characteristic, and multivariate logistic regression analyses.
RESULTS: MM or better status was achieved in 34/48 patients (median onset age: 55 years). Time from symptom onset to immunotherapy initiation was significantly shorter in those who achieved MM or better status (median: 30 days vs. 1095 days; p < 0.001). Receiver-operating characteristic analysis determined a 255-day cutoff for immunotherapy initiation, yielding sensitivity of 92.9% and specificity of 91.2% (AUC = 0.986, 95% CI: 0.962-1.000, p < 0.001). Logistic regression confirmed early immunotherapy as an independent predictor.
CONCLUSIONS: Early initiation of immunotherapy (< 255 days from onset) significantly improves the likelihood of achieving MM or better status in ocular MG. These findings support the need for prompt diagnosis and treatment to optimize outcomes.
OBJECTIVE: To identify predictive factors for achieving minimal manifestations (MM) or better status in ocular MG patients receiving immunotherapy, with a focus on the role of early intervention.
METHODS: We conducted a retrospective analysis of 48 ocular MG patients treated at our institution. Patients were categorized based on whether they achieved MM or better status. Clinical variables were analyzed using univariate, receiver-operating characteristic, and multivariate logistic regression analyses.
RESULTS: MM or better status was achieved in 34/48 patients (median onset age: 55 years). Time from symptom onset to immunotherapy initiation was significantly shorter in those who achieved MM or better status (median: 30 days vs. 1095 days; p < 0.001). Receiver-operating characteristic analysis determined a 255-day cutoff for immunotherapy initiation, yielding sensitivity of 92.9% and specificity of 91.2% (AUC = 0.986, 95% CI: 0.962-1.000, p < 0.001). Logistic regression confirmed early immunotherapy as an independent predictor.
CONCLUSIONS: Early initiation of immunotherapy (< 255 days from onset) significantly improves the likelihood of achieving MM or better status in ocular MG. These findings support the need for prompt diagnosis and treatment to optimize outcomes.